More on CGEM
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $21.67 |
|
|||
| Open | $21.67 | ||||
| 52 Wk High | $0.19 | ||||
| 52 Wk Low | $0.03 | ||||
| Day High | $21.67 | ||||
| Day Low | $20.43 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 212,134 | ||||
- Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
- Cullinan Oncology Inc. (CGEM) PT Raised to $40 at BTIG
- Stifel Reiterates Buy Rating on Cullinan Oncology Inc. (CGEM)
- TD Cowen Reiterates Buy Rating on Cullinan Oncology Inc. (CGEM)
- Cullinan Therapeutics to host investor event on Phase 3 lung cancer trial
- Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
- Zipalertinib combo shows 6-month PFS gain in lung cancer trial
- Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
- Cullinan Therapeutics to host investor event after Phase 3 lung cancer trial data
- Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
Entities mentioned with CGEM
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- H.C. Wainwright | View Related Stories »
- Show More...
